Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Transgenic Chickens: OmniChicken® & OmniClic®

  • Antibody Generation
  • OmniRat
  • OmniMouse
  • OmniChicken
  • OmniTaur
  • Bispecific Platforms

The only human Ig-transgenic chicken for the discovery of therapeutic antibodies

More than 300 million years of evolutionary distance drives divergence between mammalian and avian orthologs. OmniChicken and OmniClic offer affinity matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to highly conserved therapeutic targets.

Leverage the advantage of using distinct transgenic animals

Due to the large evolutionary distance between birds and mammals, many target antigens that are not immunogenic in rats or mice induce a strong antibody response in chickens.

Learn more about the OmniAb difference

About OmniChicken

Launched in 2016, OmniChicken is the first successfully engineered bird with an immune system that can efficiently generate human sequence antibody repertoires.

OmniChicken features:

  • A high level of functional antibody diversity is achieved through the powerful in vivo diversification process of gene conversion.
  • Patented genetic design focuses diversity in the CDR regions while maintaining conserved and highly developable framework regions based on human VH3-23 and VK3-15 or VL1-44
  • OmniChicken antibodies bind to diverse epitopes on human targets with high affinity, and typically feature excellent developability profiles

About OmniClic: A transgenic chicken that generates bispecific antibodies

The OmniClic transgenic chicken expresses a fixed VK3-15 light chain so different antibodies generated using this platform can be easily combined to form a bispecific human antibody.

Learn About OmniClic

Scientific Publications

Discovery of high affinity, pan-allelic, and panmammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.